News | July 11, 2025
Pfizer and Astellas' Xtandi combo extends survival in early prostate cancer setting
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need
Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
Lijo Chacko is the Chief Executive Officer – Middle East & Africa at Sigachi Industries
The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde
The study showed that sClever-1 is released by macrophages and blood vessel cells and binds to activated T cells
atai and Beckley Psytech plan to meet with the U.S. Food and Drug Administration (FDA) and other regulatory agencies to finalize the Phase 3 trial design.
Subscribe To Our Newsletter & Stay Updated
